Physician profile
Jamison Roberts
NPI 1528042678
$1,637.74
in general payments reported to CMS, 2019-2025
22 companies · $296 in 2025
The $296 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $142 · 2021: $156 · 2022: $169 · 2023: $196 · 2024: $473 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $245.65 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $180.11 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $162.10 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $124.34 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $111.59 | 2020-2021 | |
| Sanofi Pasteur INC. | $104.58 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $97.76 | 2024-2025 | Ycanth |
| Cranial Technologies, INC | $90.31 | 2021-2025 | Doc Band |
| Pfizer INC. | $82.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $82.03 | 2024-2025 | |
| Neos Therapeutics, Lp | $62.54 | 2019-2024 | Adzenys Xr-Odt |
| Sobi, INC | $50.80 | 2019-2023 | |
| Genentech USA, INC. | $40.76 | 2019 | |
| Merck Sharp & Dohme LLC | $38.41 | 2019-2023 | Vaqta, Gardasil 9, Vaxneuvance |
| Kaleo, INC. | $36.30 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $30.98 | 2020-2023 | Immunocap |
| Eyevance Pharmaceuticals LLC | $23.21 | 2021 | |
| Avion Pharmaceuticals | $16.69 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $16.47 | 2024 | Relexxii |
| Tris Pharma INC | $15.35 | 2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $12.95 | 2020 | |
| Mission Pharmacal Company | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamison Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.